JP2020511547A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511547A5
JP2020511547A5 JP2020501418A JP2020501418A JP2020511547A5 JP 2020511547 A5 JP2020511547 A5 JP 2020511547A5 JP 2020501418 A JP2020501418 A JP 2020501418A JP 2020501418 A JP2020501418 A JP 2020501418A JP 2020511547 A5 JP2020511547 A5 JP 2020511547A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
optionally substituted
fluorine atoms
membered ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020501418A
Other languages
English (en)
Japanese (ja)
Other versions
JP7219902B2 (ja
JP2020511547A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/023455 external-priority patent/WO2018175512A1/en
Publication of JP2020511547A publication Critical patent/JP2020511547A/ja
Publication of JP2020511547A5 publication Critical patent/JP2020511547A5/ja
Application granted granted Critical
Publication of JP7219902B2 publication Critical patent/JP7219902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020501418A 2017-03-22 2018-03-21 ブルトン型チロシンキナーゼ阻害剤 Active JP7219902B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474686P 2017-03-22 2017-03-22
US62/474,686 2017-03-22
PCT/US2018/023455 WO2018175512A1 (en) 2017-03-22 2018-03-21 Bruton's tyrosine kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2020511547A JP2020511547A (ja) 2020-04-16
JP2020511547A5 true JP2020511547A5 (US20040106767A1-20040603-C00005.png) 2021-04-30
JP7219902B2 JP7219902B2 (ja) 2023-02-09

Family

ID=63585694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020501418A Active JP7219902B2 (ja) 2017-03-22 2018-03-21 ブルトン型チロシンキナーゼ阻害剤

Country Status (13)

Country Link
US (3) US11554118B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP3601264A4 (US20040106767A1-20040603-C00005.png)
JP (1) JP7219902B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR102627756B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN110494433B (US20040106767A1-20040603-C00005.png)
AU (1) AU2018237123B2 (US20040106767A1-20040603-C00005.png)
BR (1) BR112019019588A2 (US20040106767A1-20040603-C00005.png)
CA (1) CA3055602A1 (US20040106767A1-20040603-C00005.png)
EA (1) EA201992147A1 (US20040106767A1-20040603-C00005.png)
IL (1) IL269152B2 (US20040106767A1-20040603-C00005.png)
MX (1) MX2019011116A (US20040106767A1-20040603-C00005.png)
WO (1) WO2018175512A1 (US20040106767A1-20040603-C00005.png)
ZA (1) ZA201906887B (US20040106767A1-20040603-C00005.png)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제
AU2020207953A1 (en) * 2019-01-18 2021-08-26 Hangzhou Bangshun Pharmaceutical Co., Ltd. Bruton's tyrosine kinase inhibitors
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3139795A1 (en) * 2019-05-10 2020-11-19 Henan Normal University Substituted 1-amino-1h-imidazole-5-carboxamide as bruton's tyrosine kinase inhibitors
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN111471048B (zh) * 2020-04-30 2021-06-15 成都海博为药业有限公司 一种具有含氮桥环、螺环或并环结构的化合物及其用途
CN115073468B (zh) * 2021-03-15 2023-12-22 药雅科技(上海)有限公司 咪唑并吡嗪类btk抑制剂的制备及用途
CN116348453A (zh) * 2021-04-25 2023-06-27 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058755A2 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of imidazo[1,5-a]pyridin-3-yl derivatives and related heterobicycles for targetting compounds capable of binding to g-protein coupled receptors
AU2004268918A1 (en) * 2003-09-03 2005-03-10 Galapagos Nv Imidazo(1,5-a)pyridine or imidazo(1,5-a)piperidine derivatives and their use for the preparation of medicament against 5-HT2A receptor-related disorders
WO2008022060A2 (en) * 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
EP2532235A1 (en) * 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CA2681756C (en) 2007-03-28 2015-02-24 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
US8658794B2 (en) * 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CA2831356A1 (en) 2011-03-31 2012-10-04 Emblem Technology Transfer Gmbh Imidazo [1,2-a]pyridine_compounds for use in therapy
GB2513821A (en) * 2011-06-28 2014-11-12 Andrew Levine Speech-to-text conversion
WO2013010869A1 (en) * 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
LT2734522T (lt) 2011-07-19 2019-02-11 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-il-benzamidai ir 4-imidazotriazin-1-il-benzamidai kaip btk-inhibitoriai
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
FR2985185B1 (fr) * 2012-01-04 2013-12-27 Sanofi Sa Utilisation en therapeutique de derives d'imidazopyridine
CN104080789B (zh) 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
EP2948458B1 (en) * 2013-01-23 2019-05-01 Merck Sharp & Dohme Corp. Btk inhibitors
WO2014113942A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors
JP2016533385A (ja) 2013-08-22 2016-10-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アルキニルアルコール及び使用方法
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016106652A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Biarylether imidazopyrazine btk inhibitors
WO2016106626A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
TW201718572A (zh) * 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 酪胺酸激酶抑制劑
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
CN106478633A (zh) 2015-08-27 2017-03-08 正大天晴药业集团股份有限公司 一类布鲁顿酪氨酸激酶抑制剂
US20170071962A1 (en) * 2015-09-11 2017-03-16 Acerta Pharma B.V. Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
US20170035881A1 (en) * 2015-10-19 2017-02-09 Acerta Pharma B.V. Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
MA43162A (fr) * 2015-11-06 2018-09-12 Acerta Pharma Bv Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
NZ745927A (en) * 2016-03-11 2024-05-31 Angel Pharmaceutical Co Ltd Compounds and methods for modulating bruton’s tyrosine kinase
EP3480199B1 (en) 2016-06-30 2021-03-17 Hangzhou Bangshun Pharmaceutical Co., Ltd. Imidazopyridinamine phenyl derivative and use thereof
JP6737952B2 (ja) 2016-08-17 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. チロシンキナーゼ活性を阻害するための縮合二環式化合物
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제

Similar Documents

Publication Publication Date Title
JP2020511547A5 (US20040106767A1-20040603-C00005.png)
JP2019502763A5 (US20040106767A1-20040603-C00005.png)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
WO2020227549A8 (en) MODULATORS OF THR-β AND METHODS OF USE THEREOF
JP2020521741A5 (US20040106767A1-20040603-C00005.png)
JP2018529739A5 (US20040106767A1-20040603-C00005.png)
JP2016520131A5 (US20040106767A1-20040603-C00005.png)
JP2009536620A5 (US20040106767A1-20040603-C00005.png)
RU2016150486A (ru) Ингибиторы бета-лактамазы
JP2019518766A5 (US20040106767A1-20040603-C00005.png)
JP2005505618A5 (US20040106767A1-20040603-C00005.png)
JP2018529650A5 (US20040106767A1-20040603-C00005.png)
JP2019524883A5 (US20040106767A1-20040603-C00005.png)
JP2015537020A5 (US20040106767A1-20040603-C00005.png)
JP2013010792A5 (US20040106767A1-20040603-C00005.png)
JP2017502940A5 (US20040106767A1-20040603-C00005.png)
JP2014511892A5 (US20040106767A1-20040603-C00005.png)
JP2016509047A5 (US20040106767A1-20040603-C00005.png)
JP2016518437A5 (US20040106767A1-20040603-C00005.png)
JP2016531126A5 (US20040106767A1-20040603-C00005.png)
JP2016534148A5 (US20040106767A1-20040603-C00005.png)
JP2013531029A5 (US20040106767A1-20040603-C00005.png)
JP2017511357A5 (US20040106767A1-20040603-C00005.png)
JP2013532652A5 (US20040106767A1-20040603-C00005.png)
RU2017104856A (ru) Функционализированные и замещенные индолы в качестве противораковых средств